Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk

Brezski, 2007, B cell antigen receptor-induced Rac1 activation and Rac1-dependent spreading are impaired in transitional immature B cells due to levels of membrane cholesterol, J. Immunol., 179, 4464, 10.4049/jimmunol.179.7.4464 Pucadyil, 2006, Role of cholesterol in the function and organization of G-protein coupled receptors, Prog. Lipid Res., 45, 295, 10.1016/j.plipres.2006.02.002 Mistafa, 2009, Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells, Biochem. Pharmacol., 78, 1115, 10.1016/j.bcp.2009.06.016 Sun, 2009, Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K, Circ. Res., 104, 455, 10.1161/CIRCRESAHA.108.182568 Ridsdale, 2006, Cholesterol is required for efficient endoplasmic reticulum-to-Golgi transport of secretory membrane proteins, Mol. Biol. Cell., 17, 1593, 10.1091/mbc.e05-02-0100 Glodowski, 2007, RAB-10 regulates glutamate receptor recycling in a cholesterol-dependent endocytosis pathway, Mol. Biol. Cell., 18, 4387, 10.1091/mbc.e07-05-0486 Lippincott-Schwartz, 2010, Lipids and cholesterol as regulators of traffic in the endomembrane system, Annu. Rev. Biophys., 39, 559, 10.1146/annurev.biophys.093008.131357 Vacca, 2009, Rapid constitutive and ligand-activated endocytic trafficking of P2X receptor, J. Neurochem., 109, 1031, 10.1111/j.1471-4159.2009.06029.x Vrljic, 2005, Cholesterol depletion suppresses the translational diffusion of class II major histocompatibility complex proteins in the plasma membrane, Biophys. J., 88, 334, 10.1529/biophysj.104.045989 Feingold, 2007, Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis, J. Lipid Res., 48, 2531, 10.1194/jlr.R700013-JLR200 Ponce, 2010, The effect of simvastatin on the proteome of detergent-resistant membrane domains: decreases of specific proteins previously related to cytoskeleton regulation, calcium homeostasis and cell fate, Proteomics., 10, 1954, 10.1002/pmic.200900055 Chrast, 2011, Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models, J. Lipid Res., 52, 419, 10.1194/jlr.R009761 Fredrickson, 1965, A system for phenotyping hyperlipoproteinemia, Circulation., 31, 321, 10.1161/01.CIR.31.3.321 Porter, 2011, Malformation syndromes caused by disorders of cholesterol synthesis, J. Lipid Res., 52, 6, 10.1194/jlr.R009548 Abi-Mosleh, 2009, Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells, Proc. Natl. Acad. Sci. USA., 106, 19316, 10.1073/pnas.0910916106 Rosenbaum, 2011, Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches, J. Neurochem., 116, 789, 10.1111/j.1471-4159.2010.06976.x Garver, 2010, The National Niemann-Pick Type C1 Disease Database: correlation of lipid profiles, mutations, and biochemical phenotypes, J. Lipid Res., 51, 406, 10.1194/jlr.P000331 Temel, 2007, Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe, J. Clin. Invest., 117, 1968, 10.1172/JCI30060 Liu, 2005, Investigating the allosterism of acyl-CoA:cholesterol acyltransferase (ACAT) by using various sterols: in vitro and intact cell studies, Biochem. J., 391, 389, 10.1042/BJ20050428 Gylling, 2002, Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption, J. Lipid Res., 43, 1472, 10.1194/jlr.M200155-JLR200 Simonen, 2007, The distribution of squalene and non-cholesterol sterols in lipoproteins in type 2 diabetes, Atherosclerosis., 194, 222, 10.1016/j.atherosclerosis.2006.07.030 Wiesner, 2009, Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry, J. Lipid Res., 50, 574, 10.1194/jlr.D800028-JLR200 März, 1993, Fast lipoprotein chromatography: new method of analysis for plasma lipoproteins, Clin. Chem., 39, 2276, 10.1093/clinchem/39.11.2276 Ståhlman, 2008, Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr, J. Lipid Res., 49, 481, 10.1194/jlr.D700025-JLR200 Gregg, 1986, Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis, J. Clin. Invest., 77, 1864, 10.1172/JCI112513 Salen, 1992, Increased sitosterol absorption is offset by rapid elimination to prevent accumulation in heterozygotes with sitosterolemia, Arterioscler. Thromb., 12, 563, 10.1161/01.ATV.12.5.563 Narushima, 2008, Niemann-pick C1-like 1 mediates alpha-tocopherol transport, Mol. Pharmacol., 74, 42, 10.1124/mol.107.043034 Duan, 2004, Cholesterol absorption is mainly regulated by the jejunal and ileal ATP-binding cassette sterol efflux transporters Abcg5 and Abcg8 in mice, J. Lipid Res., 45, 1312, 10.1194/jlr.M400030-JLR200 Plösch, 2004, Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor, Gastroenterology., 126, 290, 10.1053/j.gastro.2003.10.074 Wang, 2007, Quantifying anomalous intestinal sterol uptake, lymphatic transport, and biliary secretion in Abcg8( 2 / 2 ) mice, Hepatology., 45, 998, 10.1002/hep.21579 Yu, 2004, Selective sterol accumulation in ABCG5/ABCG8-deficient mice, J. Lipid Res., 45, 301, 10.1194/jlr.M300377-JLR200 Teslovich, 2010, Biological, clinical and population relevance of 95 loci for blood lipids, Nature., 466, 707, 10.1038/nature09270 Altmann, 2004, Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption, Science., 303, 1201, 10.1126/science.1093131 Sané, 2006, Localization and role of NPC1L1 in cholesterol absorption in human intestine, J. Lipid Res., 47, 2112, 10.1194/jlr.M600174-JLR200 Brown, 2007, NPC1L1 (Niemann-Pick C1-like 1) mediates sterol-specific unidirectional transport of non-esterified cholesterol in McArdle-RH7777 hepatoma cells, Biochem. J., 406, 273, 10.1042/BJ20070168 Ezzet, 2001, The plasma concentration and LDL-C relationship in patients receiving ezetimibe, J. Clin. Pharmacol., 41, 943, 10.1177/00912700122010915 Sudhop, 2002, Inhibition of intestinal cholesterol absorption by ezetimibe in humans, Circulation., 106, 1943, 10.1161/01.CIR.0000034044.95911.DC Foody, 2010, Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥ 65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study), Am. J. Cardiol., 106, 1255, 10.1016/j.amjcard.2010.06.051 Howard, 2010, The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS, Nutr. Metab. Cardiovasc. Dis., 20, 295, 10.1016/j.numecd.2010.05.002 Lioudaki, 2011, Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years, Curr. Vasc. Pharmacol., 9, 62, 10.2174/157016111793744760 Clarenbach, 2006, The lipid-lowering effect of ezetimibe in pure vegetarians, J. Lipid Res., 47, 2820, 10.1194/jlr.P600009-JLR200 Davis, 2004, Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis, J. Biol. Chem., 279, 33586, 10.1074/jbc.M405817200 Tang, 2009, Genetic inactivation of NPC1L1 protects against sitosterolemia in mice lacking ABCG5/ABCG8, J. Lipid Res., 50, 293, 10.1194/jlr.M800439-JLR200 Bosner, 1999, Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry, J. Lipid Res., 40, 302, 10.1016/S0022-2275(20)33370-8 Miettinen, 2006, Liver transplantation in a patient with sitosterolemia and cirrhosis, Gastroenterology., 130, 542, 10.1053/j.gastro.2005.10.022 Boomsma, 2003, Genetic analysis of indicators of cholesterol synthesis and absorption: lathosterol and phytosterols in Dutch twins and their parents, Twin Res., 6, 307, 10.1375/136905203322296674 Cohen, 2006, Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels, Proc. Natl. Acad. Sci. USA., 103, 1810, 10.1073/pnas.0508483103 Polisecki, 2010, Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly, J. Lipid Res., 51, 1201, 10.1194/jlr.P001172 Miettinen, 1990, Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population, Am. J. Epidemiol., 131, 20, 10.1093/oxfordjournals.aje.a115479 Fahmi, 2008, Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes, Hum. Mol. Genet., 17, 2101, 10.1093/hmg/ddn108 Wang, 2011, Molecular characterization of the NPC1L1 variants identified from cholesterol low absorbers, J. Biol. Chem., 286, 7397, 10.1074/jbc.M110.178368 Ge, 2008, The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1, Cell Metab., 7, 508, 10.1016/j.cmet.2008.04.001 Simon, 2005, Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment, Genomics., 86, 648, 10.1016/j.ygeno.2005.08.007 Pisciotta, 2007, Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients, Atherosclerosis., 194, e116, 10.1016/j.atherosclerosis.2006.10.036 Iwayanagi, 2008, HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1, Pharm. Res., 25, 1134, 10.1007/s11095-007-9496-9 Pramfalk, 2010, HNF1alpha and SREBP2 are important regulators of NPC1L1 in human liver, J. Lipid Res., 51, 1354, 10.1194/jlr.M900274-JLR200 Tremblay, 2011, Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men, J. Lipid Res., 52, 558, 10.1194/jlr.M011080 Berge, 2000, Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters, Science., 290, 1771, 10.1126/science.290.5497.1771 Lee, 2001, Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption, Nat. Genet., 27, 79, 10.1038/83799 Graf, 2003, ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion, J. Biol. Chem., 278, 48275, 10.1074/jbc.M310223200 Vrins, 2007, The sterol transporting heterodimer ABCG5/ABCG8 requires bile salts to mediate cholesterol efflux, FEBS Lett., 581, 4616, 10.1016/j.febslet.2007.08.052 Klett, 2004, Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder and intestine, BMC Gastroenterol., 4, 21, 10.1186/1471-230X-4-21 Tauscher, 2003, ABCG5 and ABCG8 are expressed in gallbladder epithelial cells, Biochem. Biophys. Res. Commun., 307, 1021, 10.1016/S0006-291X(03)01296-8 Lütjohann, 1995, Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment, J. Lipid Res., 36, 1763, 10.1016/S0022-2275(20)41495-6 Salen, 1994, Inverse relationship between plasma cholestanol concentrations and bile acid synthesis in sitosterolemia, J. Lipid Res., 35, 1878, 10.1016/S0022-2275(20)39783-2 Igel, 2003, Comparison of the intestinal uptake of cholesterol, plant sterols, and stanols in mice, J. Lipid Res., 44, 533, 10.1194/jlr.M200393-JLR200 Lam, 2002, Novel donor splice site mutation of ABCG5 gene in sitosterolemia, Mol. Genet. Metab., 75, 178, 10.1006/mgme.2001.3285 Wang, 2004, Phenotypic heterogeneity of sitosterolemia, J. Lipid Res., 45, 2361, 10.1194/jlr.M400310-JLR200 Su, 2006, Clinical and molecular genetic analysis of a family with sitosterolemia and co-existing erythrocyte and platelet abnormalities, Haematologica., 91, 1392 Togo, 2009, Identification of a novel mutation for phytosterolemia. Genetic analyses of 2 cases, Clin. Chim. Acta., 401, 165, 10.1016/j.cca.2008.10.026 Niu, 2010, Clinical observations, molecular genetic analysis, and treatment of sitosterolemia in infants and children, J. Inherit. Metab. Dis., 33, 437, 10.1007/s10545-010-9126-2 Salen, 1985, Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis, J. Lipid Res., 26, 1126, 10.1016/S0022-2275(20)34286-3 Hubacek, 2001, Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia, Hum. Mutat., 18, 359, 10.1002/humu.1206 Heimer, 2002, Structure of polydispersed colloids characterised by light scattering and electron microscopy, Adv. Colloid Interface Sci., 98, 1, 10.1016/S0001-8686(01)00090-2 Katayama, 2003, A 19-year-old man with myocardial infarction and sitosterolemia, Intern. Med., 42, 591, 10.2169/internalmedicine.42.591 Mushtaq, 2007, Adrenal insufficiency in phytosterolaemia, Eur. J. Endocrinol., 157, S61, 10.1530/EJE-07-0222 Rees, 2005, Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia, Br. J. Haematol., 130, 297, 10.1111/j.1365-2141.2005.05599.x Bhattacharyya, 1974, Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters, J. Clin. Invest., 53, 1033, 10.1172/JCI107640 Rios, 2010, Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia, Hum. Mol. Genet., 19, 4313, 10.1093/hmg/ddq352 Nguyen, 1988, The effect of abnormal plasma and cellular sterol content and composition on low density lipoprotein uptake and degradation by monocytes and lymphocytes in sitosterolemia with xanthomatosis, Metabolism., 37, 346, 10.1016/0026-0495(88)90134-5 Heimerl, 2002, Mutations in the human ATP-binding cassette transporters ABCG5 and ABCG8 in sitosterolemia, Hum. Mutat., 20, 151, 10.1002/humu.9047 Cheng, 2003, Sitosterolaemia and xanthomatosis in a child, Hong Kong Med. J., 9, 206 Sehayek, 2004, Phytosterolemia on the island of Kosrae: founder effect for a novel ABCG8 mutation results in high carrier rate and increased plasma plant sterol levels, J. Lipid Res., 45, 1608, 10.1194/jlr.M400006-JLR200 Mannucci, 2007, Beta-sitosterolaemia: a new nonsense mutation in the ABCG5 gene, Eur. J. Clin. Invest., 37, 997, 10.1111/j.1365-2362.2007.01880.x Lu, 2001, Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively, Am. J. Hum. Genet., 69, 278, 10.1086/321294 Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor, Proc. Natl. Acad. Sci. USA., 105, 13045, 10.1073/pnas.0806312105 Johnson, 2010, Bile acids stimulate ATP hydrolysis in the purified cholesterol transporter ABCG5/G8, Biochemistry., 49, 3403, 10.1021/bi902064g Graf, 2004, Missense mutations in ABCG5 and ABCG8 disrupt heterodimerization and trafficking, J. Biol. Chem., 279, 24881, 10.1074/jbc.M402634200 Kenny, 2009, Systematic haplotype analysis resolves a complex plasma plant sterol locus on the Micronesian Island of Kosrae, Proc. Natl. Acad. Sci. USA., 106, 13886, 10.1073/pnas.0907336106 Honda, 1998, J. Lipid Res., 39, 44, 10.1016/S0022-2275(20)34201-2 Nguyen, 1990, Unexpected failure of bile acid malabsorption to stimulate cholesterol synthesis in sitosterolemia with xanthomatosis. Comparison with lovastatin, Arteriosclerosis., 10, 289, 10.1161/01.ATV.10.2.289 Nguyen, 1991, Regulation of cholesterol biosynthesis in sitosterolemia: effects of lovastatin, cholestyramine, and dietary sterol restriction, J. Lipid Res., 32, 1941, 10.1016/S0022-2275(20)41897-8 Nguyen, 1990, A molecular defect in hepatic cholesterol biosynthesis in sitosterolemia with xanthomatosis, J. Clin. Invest., 86, 923, 10.1172/JCI114794 Berge, 2002, Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8, J. Lipid Res., 43, 486, 10.1016/S0022-2275(20)30155-3 Gylling, 2004, Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity, J. Lipid Res., 45, 1660, 10.1194/jlr.M300522-JLR200 Jakulj, 2010, ABCG5/G8 polymorphisms and markers of cholesterol metabolism: systematic review and meta-analysis, J. Lipid Res., 51, 3016, 10.1194/jlr.M008128 Teupser, 2010, Genetic regulation of serum phytosterol levels and risk of coronary artery disease, Circ. Cardiovasc. Genet., 3, 331, 10.1161/CIRCGENETICS.109.907873 Buch, 2007, A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease, Nat. Genet., 39, 995, 10.1038/ng2101 Grünhage, 2007, Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol, Hepatology., 46, 793, 10.1002/hep.21847 Katsika, 2010, Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype, J. Intern. Med., 268, 279, 10.1111/j.1365-2796.2010.02249.x Kuo, 2008, Significant association of ABCG5 604Q and ABCG8 D19H polymorphisms with gallstone disease, Br. J. Surg., 95, 1005, 10.1002/bjs.6178 Siddapuram, 2010, Hepatic cholesterol transporter ABCG8 polymorphisms in gallstone disease in an Indian population, J. Gastroenterol. Hepatol., 25, 1093, 10.1111/j.1440-1746.2010.06309.x Stender, 2011, Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population, Hepatology., 53, 640, 10.1002/hep.24046 Chiang, 2009, Bile acids: regulation of synthesis, J. Lipid Res., 50, 1955, 10.1194/jlr.R900010-JLR200 Schmidt, 2010, Regulation of bile acid synthesis by fat-soluble vitamins A and D, J. Biol. Chem., 285, 14486, 10.1074/jbc.M110.116004 Tint, 1994, Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome, N. Engl. J. Med., 330, 107, 10.1056/NEJM199401133300205 Burkhardt, 2008, Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13, Arterioscler. Thromb. Vasc. Biol., 28, 2078, 10.1161/ATVBAHA.108.172288 Hiura, 2010, Association of the functional variant in the 3-hydroxy-3-methylglutaryl-coenzyme a reductase gene with low-density lipoprotein-cholesterol in Japanese, Circ. J., 74, 518, 10.1253/circj.CJ-09-0790 Fisher, 2011, Ubiquitination regulates the assembly of VLDL in HepG2 cells and is the committing step of the apoB-100 ERAD pathway, J. Lipid Res., 52, 1170, 10.1194/jlr.M011726 Rutledge, 2010, Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly, Biochem. Cell Biol., 88, 251, 10.1139/O09-168 Qiu, 2011, Hepatic autophagy mediates endoplasmic reticulum stress-induced degradation of misfolded apolipoprotein B, Hepatology., 53, 1515, 10.1002/hep.24269 Jiang, 2005, Limited proteolysis and biophysical characterization of the lipovitellin homology region in apolipoprotein B, Biochemistry., 44, 1163, 10.1021/bi048286y Jiang, 2006, Defining lipid-interacting domains in the N-terminal region of apolipoprotein B, Biochemistry., 45, 11799, 10.1021/bi060600w Wang, 2010, Interfacial properties of apolipoprotein B292-593 (B6.4-13) and B611-782 (B13-17). Insights into the structure of the lipovitellin homology region in apolipoprotein B, Biochemistry., 49, 3898, 10.1021/bi100056v Ledford, 2009, Structural and dynamic interfacial properties of the lipoprotein initiating domain of apolipoprotein B, J. Lipid Res., 50, 108, 10.1194/jlr.M800324-JLR200 Manchekar, 2008, Charged amino acid residues 997-1000 of human apolipoprotein B100 are critical for the initiation of lipoprotein assembly and the formation of a stable lipidated primordial particle in McA-RH7777 cells, J. Biol. Chem., 283, 29251, 10.1074/jbc.M804912200 Carraway, 2000, Specificity of lipid incorporation is determined by sequences in the N-terminal 37 of apoB, Biochemistry., 39, 9737, 10.1021/bi000791h Ren, 2010, Model of human low-density lipoprotein and bound receptor based on cryoEM, Proc. Natl. Acad. Sci. USA., 107, 1059, 10.1073/pnas.0908004107 Iglesias, 2010, Severe hyperthyroidism: aetiology, clinical features and treatment outcome, Clin. Endocrinol. (Oxf.)., 72, 551, 10.1111/j.1365-2265.2009.03682.x Huang, 1991, ApoB gene nonsense and splicing mutations in a compound heterozygote for familial hypobetalipoproteinemia, J. Lipid Res., 32, 1341, 10.1016/S0022-2275(20)41964-9 Najah, 2009, Identification of patients with abetalipoproteinemia and homozygous familial hypobetalipoproteinemia in Tunisia, Clin. Chim. Acta., 401, 51, 10.1016/j.cca.2008.11.012 Aguilar-Salinas, 1995, Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B, Arterioscler. Thromb. Vasc. Biol., 15, 71, 10.1161/01.ATV.15.1.71 Elias, 1999, Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia, Arterioscler. Thromb. Vasc. Biol., 19, 2714, 10.1161/01.ATV.19.11.2714 Latour, 1997, Metabolism of apolipoprotein B-100 in a kindred with familial hypobetalipoproteinemia without a truncated form of apoB, J. Lipid Res., 38, 592, 10.1016/S0022-2275(20)37267-9 Hooper, 2007, Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia, J. Clin. Endocrinol. Metab., 92, 1474, 10.1210/jc.2006-1998 Lancellotti, 2004, Hypobetalipoproteinemia with an apparently recessive inheritance due to a “de novo” mutation of apolipoprotein B, Biochim. Biophys. Acta., 1688, 61, 10.1016/j.bbadis.2003.11.002 Tarugi, 2001, Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene, J. Lipid Res., 42, 1552, 10.1016/S0022-2275(20)32208-2 Ruotolo, 1998, Hypobetalipoproteinemia associated with apo B-48.4, a truncated protein only 14 amino acids longer than apo B-48, Atherosclerosis., 137, 125, 10.1016/S0021-9150(97)00262-1 Takahashi, 2001, Clinical characterization of a case with familial hypobetalipoproteinemia caused by apo B-76, a new truncation of apolipoprotein B, combined with apo E2/E2 phenotype, Intern. Med., 40, 1015, 10.2169/internalmedicine.40.1015 Talmud, 1994, Donor splice mutation generates a lipid-associated apolipoprotein B-27.6 in a patient with homozygous hypobetalipoproteinemia, J. Lipid Res., 35, 468, 10.1016/S0022-2275(20)41197-6 Ohashi, 1998, A truncated species of apolipoprotein B (B-38.7) in a patient with homozygous hypobetalipoproteinemia associated with diabetes mellitus, Arterioscler. Thromb. Vasc. Biol., 18, 1330, 10.1161/01.ATV.18.8.1330 Young, 1994, Asymptomatic homozygous hypobetalipoproteinemia associated with apolipoprotein B45.2, Hum. Mol. Genet., 3, 741, 10.1093/hmg/3.5.741 Lancellotti, 2005, Pediatric gallstone disease in familial hypobetalipoproteinemia, J. Hepatol., 43, 188, 10.1016/j.jhep.2005.03.012 Krul, 1989, Two distinct truncated apolipoprotein B species in a kindred with hypobetalipoproteinemia, Arteriosclerosis., 9, 856, 10.1161/01.ATV.9.6.856 Young, 1989, Familial hypobetalipoproteinemia associated with a mutant species of apolipoprotein B (B-46), N. Engl. J. Med., 320, 1604, 10.1056/NEJM198906153202407 Farese, 1992, A truncated species of apolipoprotein B, B-83, associated with hypobetalipoproteinemia, J. Lipid Res., 33, 569, 10.1016/S0022-2275(20)41622-0 Pulai, 1997, Normal intestinal dietary fat and cholesterol absorption, intestinal apolipoprotein B (ApoB) mRNA levels, and ApoB-48 synthesis in a hypobetalipoproteinemic kindred without any ApoB truncation, Metabolism., 46, 1095, 10.1016/S0026-0495(97)90285-7 Pulai, 1998, Donor splice mutation (665 + 1 G_T) in familial hypobetalipoproteinemia with no detectable apoB truncation, Am. J. Med. Genet., 80, 218, 10.1002/(SICI)1096-8628(19981116)80:3<218::AID-AJMG7>3.0.CO;2-0 Groenewegen, 1994, Dysbetalipoproteinemia in a kindred with hypobetalipoproteinemia due to mutations in the genes for ApoB (ApoB-70.5) and ApoE (ApoE2), Arterioscler. Thromb., 14, 1695, 10.1161/01.ATV.14.11.1695 Nielsen, 1998, Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins, Circulation., 98, 13, 10.1161/01.CIR.98.1.13 Gautier, 2010, Human luteinized granulosa cells secrete apoB100-containing lipoproteins, J. Lipid Res., 51, 2245, 10.1194/jlr.M005181 Kaser, 2008, Microsomal triglyceride transfer protein regulates endogenous and exogenous antigen presentation by group 1 CD1 molecules, Eur. J. Immunol., 38, 2351, 10.1002/eji.200738102 Krzystanek, 2010, Expression of apolipoprotein B in the kidney attenuates renal lipid accumulation, J. Biol. Chem., 285, 10583, 10.1074/jbc.M109.078006 Yue, 2005, Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL, Atherosclerosis., 178, 107, 10.1016/j.atherosclerosis.2004.06.020 Ikewaki, 2004, Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency, J. Lipid Res., 45, 1302, 10.1194/jlr.M400020-JLR200 Mensenkamp, 1999, Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver, J. Biol. Chem., 274, 35711, 10.1074/jbc.274.50.35711 Demant, 1991, Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects, J. Clin. Invest., 88, 1490, 10.1172/JCI115459 Gillard, 2009, Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells, Biochim. Biophys. Acta., 1791, 1125, 10.1016/j.bbalip.2009.07.004 Gusarova, 2007, Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E, J. Biol. Chem., 282, 19453, 10.1074/jbc.M700475200 Wang, 2007, Proteomic and lipid characterization of apolipoprotein B-free luminal lipid droplets from mouse liver microsomes: implications for very low density lipoprotein assembly, J. Biol. Chem., 282, 33218, 10.1074/jbc.M706841200 Lin, 2006, A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation, Am. J. Physiol. Gastrointest. Liver Physiol., 290, G1170, 10.1152/ajpgi.00402.2005 Tarugi, 2007, Molecular diagnosis of hypobetalipoproteinemia: an ENID review, Atherosclerosis., 195, e19, 10.1016/j.atherosclerosis.2007.05.003 Zhong, 2010, Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B, J. Biol. Chem., 285, 6453, 10.1074/jbc.M109.060467 Chen, 2000, A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides, J. Biol. Chem., 275, 32807, 10.1074/jbc.M004913200 Burnett, 2003, A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia, J. Biol. Chem., 278, 13442, 10.1074/jbc.M300235200 Noto, 2009, Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia, Atherosclerosis., 206, 193, 10.1016/j.atherosclerosis.2009.01.037 Benn, 2008, Common and rare alleles in apolipoprotein B contribute to plasma levels of low-density lipoprotein cholesterol in the general population, J. Clin. Endocrinol. Metab., 93, 1038, 10.1210/jc.2007-1365 Narcisi, 1995, Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia, Am. J. Hum. Genet., 57, 1298 Berriot-Varoqueaux, 2000, The role of the microsomal triglygeride transfer protein in abetalipoproteinemia, Annu. Rev. Nutr., 20, 663, 10.1146/annurev.nutr.20.1.663 Chardon, 2009, Identification of two novel mutations and long-term follow-up in abetalipoproteinemia: a report of four cases, Eur. J. Pediatr., 168, 983, 10.1007/s00431-008-0888-6 Zamel, 2008, Abetalipoproteinemia: two case reports and literature review, Orphanet J. Rare Dis., 3, 19, 10.1186/1750-1172-3-19 Blum, 1982, Role of apolipoprotein E-containing lipoproteins in abetalipoproteinemia, J. Clin. Invest., 70, 1157, 10.1172/JCI110714 Ikewaki, 1994, In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism, J. Lipid Res., 35, 1809, 10.1016/S0022-2275(20)39776-5 Illingworth, 1980, Lipid metabolism in abetalipoproteinemia: a study of cholesterol absorption and sterol balance in two patients, Gastroenterology., 78, 68, 10.1016/0016-5085(80)90194-8 Kuriyama, 1999, Blood dolichols in a patient with abetalipoproteinaemia, Ann. Clin. Biochem., 36, 176, 10.1177/000456329903600207 Iqbal, 2008, Microsomal triglyceride transfer protein enhances cellular cholesteryl esterification by relieving product inhibition, J. Biol. Chem., 283, 19967, 10.1074/jbc.M800398200 Xie, 2006, Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency, J. Biol. Chem., 281, 4075, 10.1074/jbc.M510622200 Mohler, 2007, Identification of a novel isoform of microsomal triglyceride transfer protein, J. Biol. Chem., 282, 26981, 10.1074/jbc.M700500200 Goodman, 1983, Cholesterol turnover and metabolism in two patients with abetalipoproteinemia, J. Lipid Res., 24, 1605, 10.1016/S0022-2275(20)37859-7 Musunuru, 2010, Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia, N. Engl. J. Med., 363, 2220, 10.1056/NEJMoa1002926 Koishi, 2002, Angptl3 regulates lipid metabolism in mice, Nat. Genet., 30, 151, 10.1038/ng814 Köster, 2005, Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism, Endocrinology., 146, 4943, 10.1210/en.2005-0476 Romeo, 2009, Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans, J. Clin. Invest., 119, 70 Moon, 2008, Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemic subjects, Clin. Chim. Acta., 398, 99, 10.1016/j.cca.2008.08.021 Liu, 2010, Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases, J. Biol. Chem., 285, 27561, 10.1074/jbc.M110.144279 Shan, 2009, The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms, J. Biol. Chem., 284, 1419, 10.1074/jbc.M808477200 Shimamura, 2007, Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase, Arterioscler. Thromb. Vasc. Biol., 27, 366, 10.1161/01.ATV.0000252827.51626.89 Charcosset, 2008, Anderson or chylomicron retention disease: molecular impact of five mutations in the SAR1B gene on the structure and the functionality of Sar1b protein, Mol. Genet. Metab., 93, 74, 10.1016/j.ymgme.2007.08.120 Dannoura, 1999, Anderson’s disease: exclusion of apolipoprotein and intracellular lipid transport genes, Arterioscler. Thromb. Vasc. Biol., 19, 2494, 10.1161/01.ATV.19.10.2494 Nemeth, 1995, Studies on lipoprotein metabolism in a family with jejunal chylomicron retention, Eur. J. Clin. Invest., 25, 271, 10.1111/j.1365-2362.1995.tb01559.x Roy, 1987, Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B. Chylomicron retention disease, Gastroenterology., 92, 390, 10.1016/0016-5085(87)90133-8 Treepongkaruna, 2009, Novel missense mutations of SAR1B gene in an infant with chylomicron retention disease, J. Pediatr. Gastroenterol. Nutr., 48, 370, 10.1097/MPG.0b013e318183188f Cefalù, 2010, Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene, Metabolism., 59, 463, 10.1016/j.metabol.2009.07.042 Bouma, 1986, Hypobetalipoproteinemia with accumulation of an apoprotein B-like protein in intestinal cells. Immunoenzymatic and biochemical characterization of seven cases of Anderson’s disease, J. Clin. Invest., 78, 398, 10.1172/JCI112590 Peretti, 2009, Chylomicron retention disease: a long term study of two cohorts, Mol. Genet. Metab., 97, 136, 10.1016/j.ymgme.2009.02.003 Peretti, 2010, Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers, Orphanet J. Rare Dis., 5, 24, 10.1186/1750-1172-5-24 Levy, 1987, Intestinal apoB synthesis, lipids, and lipoproteins in chylomicron retention disease, J. Lipid Res., 28, 1263, 10.1016/S0022-2275(20)38593-X Jones, 2003, Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders, Nat. Genet., 34, 29, 10.1038/ng1145 Georges, 2011, Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson’s disease (Chylomicron retention disease), Orphanet J. Rare Dis., 6, 1, 10.1186/1750-1172-6-1 Shoulders, 2004, The intracellular transport of chylomicrons requires the small GTPase, Sar1b, Curr. Opin. Lipidol., 15, 191, 10.1097/00041433-200404000-00012 Lee, 2007, Molecular mechanisms of COPII vesicle formation, Semin. Cell Dev. Biol., 18, 424, 10.1016/j.semcdb.2007.06.007 Stagg, 2006, Structure of the Sec13/31 COPII coat cage, Nature., 439, 234, 10.1038/nature04339 Stagg, 2008, Structural basis for cargo regulation of COPII coat assembly, Cell., 134, 474, 10.1016/j.cell.2008.06.024 Bi, 2002, Structure of the Sec23/24-Sar1 pre-budding complex of the COPII vesicle coat, Nature., 419, 271, 10.1038/nature01040 Rao, 2006, An open conformation of switch I revealed by Sar1-GDP crystal structure at low Mg2+, Biochem. Biophys. Res. Commun., 348, 908, 10.1016/j.bbrc.2006.07.148 Hermey, 2009, The Vps10p-domain receptor family, Cell. Mol. Life Sci., 66, 2677, 10.1007/s00018-009-0043-1 Chen, 2005, Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway, J. Neurosci., 25, 6156, 10.1523/JNEUROSCI.1017-05.2005 Nielsen, 1999, Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase, J. Biol. Chem., 274, 8832, 10.1074/jbc.274.13.8832 Wähe, 2010, Golgi-to-phagosome transport of acid sphingomyelinase and prosaposin is mediated by sortilin, J. Cell Sci., 123, 2502, 10.1242/jcs.067686 Yuan, 2010, A stretch of 17 amino acids in the prosaposin C terminus is critical for its binding to sortilin and targeting to lysosomes, J. Histochem. Cytochem., 58, 287, 10.1369/jhc.2009.955203 Canuel, 2008, AP-1 and retromer play opposite roles in the trafficking of sortilin between the Golgi apparatus and the lysosomes, Biochem. Biophys. Res. Commun., 366, 724, 10.1016/j.bbrc.2007.12.015 Hu, 2010, Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin, Neuron., 68, 654, 10.1016/j.neuron.2010.09.034 Lefrancois, 2003, The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin, EMBO J., 22, 6430, 10.1093/emboj/cdg629 Petersen, 1997, Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography, J. Biol. Chem., 272, 3599, 10.1074/jbc.272.6.3599 Kjolby, 2010, Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export, Cell Metab., 12, 213, 10.1016/j.cmet.2010.08.006 Musunuru, 2010, From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus, Nature., 466, 714, 10.1038/nature09266 Jansen, 2007, Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury, Nat. Neurosci., 10, 1449, 10.1038/nn2000 Zeng, 2009, The inactivation of the sortilin gene leads to a partial disruption of prosaposin trafficking to the lysosomes, Exp. Cell Res., 315, 3112, 10.1016/j.yexcr.2009.08.016 Linsel-Nitschke, 2010, Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease, Atherosclerosis., 208, 183, 10.1016/j.atherosclerosis.2009.06.034 Gupta, 2010, Association of common DNA sequence variants at 33 genetic loci with blood lipids in individuals of African ancestry from Jamaica, Hum. Genet., 128, 557, 10.1007/s00439-010-0887-3 Nakayama, 2009, Large scale replication analysis of loci associated with lipid concentrations in a Japanese population, J. Med. Genet., 46, 370, 10.1136/jmg.2008.064063 Hegedus, 2006, Tribbles: novel regulators of cell function; evolutionary aspects, Cell. Mol. Life Sci., 63, 1632, 10.1007/s00018-006-6007-9 Burkhardt, 2010, Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice, J. Clin. Invest., 120, 4410, 10.1172/JCI44213 Sung, 2007, Human tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways, J. Biol. Chem., 282, 18379, 10.1074/jbc.M610792200 Varbo, 2011, TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population, Arterioscler. Thromb. Vasc. Biol., 31, 451, 10.1161/ATVBAHA.110.216333 Boswell, 2004, Global defects in the expression and function of the low density lipoprotein receptor (LDLR) associated with two familial hypercholesterolemia mutations resulting in misfolding of the LDLR epidermal growth factor-AB pair, J. Biol. Chem., 279, 30611, 10.1074/jbc.M401412200 Huang, 2010, Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor, J. Lipid Res., 51, 297, 10.1194/jlr.M000422 Ranheim, 2006, Model system for phenotypic characterization of sequence variations in the LDL receptor gene, Clin. Chem., 52, 1469, 10.1373/clinchem.2006.068627 Tveten, 2007, 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor, FEBS J., 274, 1881, 10.1111/j.1742-4658.2007.05735.x Zhao, 2009, The role of calcium in lipoprotein release by the low-density lipoprotein receptor, Biochemistry., 48, 7313, 10.1021/bi900214u Kwon, 2009, Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol, Cell., 137, 1213, 10.1016/j.cell.2009.03.049 Urano, 2008, Transport of LDL-derived cholesterol from the NPC1 compartment to the ER involves the trans-Golgi network and the SNARE protein complex, Proc. Natl. Acad. Sci. USA., 105, 16513, 10.1073/pnas.0807450105 Wang, 2010, Identification of surface residues on Niemann-Pick C2 essential for hydrophobic handoff of cholesterol to NPC1 in lysosomes, Cell Metab., 12, 166, 10.1016/j.cmet.2010.05.016 Leigh, 2008, Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database, Ann. Hum. Genet., 72, 485, 10.1111/j.1469-1809.2008.00436.x Leigh, 2009, Commentary PCSK9 variants: a new database, Atherosclerosis., 203, 32, 10.1016/j.atherosclerosis.2009.02.006 Marduel, 2010, Molecular spectrum of autosomal dominant hypercholesterolemia in France, Hum. Mutat., 31, E1811, 10.1002/humu.21348 Fouchier, 2005, Update of the molecular basis of familial hypercholesterolemia in The Netherlands, Hum. Mutat., 26, 550, 10.1002/humu.20256 Abifadel, 2009, The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene, Hum. Mutat., 30, E682, 10.1002/humu.21002 Dedoussis, 2004, LDL-receptor mutations in Europe, Hum. Mutat., 24, 443, 10.1002/humu.20105 Durst, 2001, Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews, Am. J. Hum. Genet., 68, 1172, 10.1086/320123 Lombardi, 2000, Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands, Clin. Genet., 57, 116, 10.1034/j.1399-0004.2000.570205.x Whittall, 2002, The intron 14 2140+5G>A variant in the low density lipoprotein receptor gene has no effect on plasma cholesterol levels, J. Med. Genet., 39, e57, 10.1136/jmg.39.9.e57 Bourbon, 2009, Genetic diagnosis of familial hypercholesterolaemia: the importance of functional analysis of potential splice-site mutations, J. Med. Genet., 46, 352, 10.1136/jmg.2007.057000 Rabacchi, 2009, An apparent inconsistency in parent to offspring transmission of point mutations of LDLR gene in familial hypercholesterolemia, Clin. Chim. Acta., 406, 75, 10.1016/j.cca.2009.05.017 Chmara, 2010, Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations, J. Appl. Genet., 51, 95, 10.1007/BF03195716 Holla, 2005, Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA, Clin. Chim. Acta., 356, 164, 10.1016/j.cccn.2005.01.028 Taylor, 2009, Multiplex ligation-dependent probe amplification analysis to screen for deletions and duplications of the LDLR gene in patients with familial hypercholesterolaemia, Clin. Genet., 76, 69, 10.1111/j.1399-0004.2009.01168.x Tosi, 2007, Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic, Atherosclerosis., 194, 102, 10.1016/j.atherosclerosis.2006.10.003 Wang, 2005, Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia, J. Lipid Res., 46, 366, 10.1194/jlr.D400030-JLR200 Chiou, 2010, Detection of mutations and large rearrangements of the low-density lipoprotein receptor gene in Taiwanese patients with familial hypercholesterolemia, Am. J. Cardiol., 105, 1752, 10.1016/j.amjcard.2010.01.356 Bourbon, 2007, A rare polymorphism in the low density lipoprotein (LDL) gene that affects mRNA splicing, Atherosclerosis., 195, e17, 10.1016/j.atherosclerosis.2007.01.034 Defesche, 2008, Silent exonic mutations in the low-density lipoprotein receptor gene that cause familial hypercholesterolemia by affecting mRNA splicing, Clin. Genet., 73, 573, 10.1111/j.1399-0004.2008.00999.x Civeira, 2008, Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting, J. Am. Coll. Cardiol., 52, 1546, 10.1016/j.jacc.2008.06.050 Bertolini, 2000, Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype, Arterioscler. Thromb. Vasc. Biol., 20, E41, 10.1161/01.ATV.20.9.e41 Pisciotta, 2006, Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison, Atherosclerosis., 188, 398, 10.1016/j.atherosclerosis.2005.11.016 Junyent, 2008, Femoral atherosclerosis in heterozygous familial hypercholesterolemia: influence of the genetic defect, Arterioscler. Thromb. Vasc. Biol., 28, 580, 10.1161/ATVBAHA.107.153841 Deiana, 2000, Influence of beta(0)-thalassemia on the phenotypic expression of heterozygous familial hypercholesterolemia: a study of patients with familial hypercholesterolemia from Sardinia, Arterioscler. Thromb. Vasc. Biol., 20, 236, 10.1161/01.ATV.20.1.236 Ricchi, 2009, Hypocholesterolemia in adult patients with thalassemia: a link with the severity of genotype in thalassemia intermedia patients, Eur. J. Haematol., 82, 219, 10.1111/j.1600-0609.2008.01195.x Shalev, 2007, Hypocholesterolemia in chronic anemias with increased erythropoietic activity, Am. J. Hematol., 82, 199, 10.1002/ajh.20804 Chebil-Laradi, 1994, [Screening of hemoglobinopathies and molecular analysis of beta-thalassemia in Central Tunisia], Arch. Pediatr., 1, 1100 Jelassi, 2010, Moderate phenotypic expression of familial hypercholesterolemia in Tunisia, Clin. Chim. Acta., 411, 735, 10.1016/j.cca.2010.02.008 Vuorio, 1997, Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study, Arterioscler. Thromb. Vasc. Biol., 17, 3127, 10.1161/01.ATV.17.11.3127 Lambert, 2001, Determinants of lipid level variability in French-Canadian children with familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 21, 979, 10.1161/01.ATV.21.6.979 Bertolini, 2004, Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia, Atherosclerosis., 174, 57, 10.1016/j.atherosclerosis.2003.12.037 Dong, 1994, Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms, J. Biol. Chem., 269, 22358, 10.1016/S0021-9258(17)31797-0 Wilson, 1991, Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E, Science., 252, 1817, 10.1126/science.2063194 Altenburg, 2008, Human LDL receptor enhances sequestration of ApoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice, Arterioscler. Thromb. Vasc. Biol., 28, 1104, 10.1161/ATVBAHA.108.164863 Klos, 2008, APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels, Hum. Mol. Genet., 17, 2039, 10.1093/hmg/ddn101 de Man, 1998, Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase, Atherosclerosis., 136, 255, 10.1016/S0021-9150(97)00218-9 Futamura, 2005, Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces, J. Biol. Chem., 280, 5414, 10.1074/jbc.M411719200 Yamauchi, 2008, Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study, Biochemistry., 47, 6702, 10.1021/bi8003999 Yu, 2001, LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice, J. Clin. Invest., 107, 1387, 10.1172/JCI11750 Knouff, 2001, Doubling expression of the low density lipoprotein receptor by truncation of the 3 ′ -untranslated region sequence ameliorates type iii hyperlipoproteinemia in mice expressing the human apoe2 isoform, J. Biol. Chem., 276, 3856, 10.1074/jbc.M009423200 Malloy, 2004, Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3, Arterioscler. Thromb. Vasc. Biol., 24, 91, 10.1161/01.ATV.0000094963.07902.FB Heeren, 2004, Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation, J. Biol. Chem., 279, 55483, 10.1074/jbc.M409324200 Mann, 1995, Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146 → Glu), J. Clin. Invest., 96, 1100, 10.1172/JCI118096 Tybjaerg-Hansen, 2005, Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations, Arterioscler. Thromb. Vasc. Biol., 25, 211, 10.1161/01.ATV.0000149380.94984.f0 Blasiole, 2008, Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB, J. Biol. Chem., 283, 11374, 10.1074/jbc.M710457200 Larsson, 2004, The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver, J. Biol. Chem., 279, 831, 10.1074/jbc.M303057200 Millar, 2005, Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production, Arterioscler. Thromb. Vasc. Biol., 25, 560, 10.1161/01.ATV.0000155323.18856.a2 Tremblay, 2004, Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation, J. Lipid Res., 45, 866, 10.1194/jlr.M300448-JLR200 Michaely, 2007, Identification of a VLDL-induced, FDNPVY-independent internalization mechanism for the LDLR, EMBO J., 26, 3273, 10.1038/sj.emboj.7601769 Linsel-Nitschke, 2008, Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease–a Mendelian Randomisation study, PLoS ONE., 3, e2986, 10.1371/journal.pone.0002986 Zhu, 2007, A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol, Hum. Mol. Genet., 16, 1765, 10.1093/hmg/ddm124 Zou, 2008, Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer’s disease, Hum. Mol. Genet., 17, 929, 10.1093/hmg/ddm365 Marcel, 1982, Mapping of antigenic determinants of human apolipoprotein B using monoclonal antibodies against low density lipoproteins, J. Biol. Chem., 257, 13165, 10.1016/S0021-9258(18)33420-3 Milne, 1989, The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B, J. Biol. Chem., 264, 19754, 10.1016/S0021-9258(19)47176-7 Pease, 1990, Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100, J. Biol. Chem., 265, 553, 10.1016/S0021-9258(19)40266-4 Law, 1990, A cross-species comparison of the apolipoprotein B domain that binds to the LDL receptor, J. Lipid Res., 31, 1109, 10.1016/S0022-2275(20)42751-8 Borén, 1998, Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding, J. Clin. Invest., 101, 2658, 10.1172/JCI2265 Johnson, 2008, Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences, Arterioscler. Thromb. Vasc. Biol., 28, 1745, 10.1161/ATVBAHA.108.169680 Chatterton, 1995, Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface, J. Lipid Res., 36, 2027, 10.1016/S0022-2275(20)41120-4 Borén, 2001, The molecular mechanism for the genetic disorder familial defective apolipoprotein B100, J. Biol. Chem., 276, 9214, 10.1074/jbc.M008890200 Gabelli, 1996, Homozygous familial hypobetalipoproteinemia. Increased LDL catabolism in hypobetalipoproteinemia due to a truncated apolipoprotein B species, apo B-87Padova, Arterioscler. Thromb. Vasc. Biol., 16, 1189, 10.1161/01.ATV.16.9.1189 Parhofer, 1990, Enhanced clearance from plasma of low density lipoproteins containing a truncated apolipoprotein, apoB-89, J. Lipid Res., 31, 2001, 10.1016/S0022-2275(20)42264-3 Soria, 1989, Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100, Proc. Natl. Acad. Sci. USA., 86, 587, 10.1073/pnas.86.2.587 Real, 2003, Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients from a South European population, Eur. J. Hum. Genet., 11, 959, 10.1038/sj.ejhg.5201079 Viola, 2001, Apolipoprotein B Arg3500Gln mutation prevalence in children with hypercholesterolemia: a French multicenter study, J. Pediatr. Gastroenterol. Nutr., 33, 122, 10.1097/00005176-200108000-00005 Gasparovic, 2007, Familial defective apolipoprotein B-100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity?, Atherosclerosis., 194, e95, 10.1016/j.atherosclerosis.2006.10.015 Bourbon, 2008, Familial hypercholesterolaemia in Portugal, Atherosclerosis., 196, 633, 10.1016/j.atherosclerosis.2007.07.019 Dedoussis, 2004, Molecular characterization of familial hypercholesterolemia in German and Greek patients, Hum. Mutat., 23, 285, 10.1002/humu.9218 Taylor, 2007, Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia, Clin. Genet., 71, 561, 10.1111/j.1399-0004.2007.00807.x Tai, 2001, Compound heterozygous familial hypercholesterolemia and familial defective apolipoprotein B-100 produce exaggerated hypercholesterolemia, Clin. Chem., 47, 438, 10.1093/clinchem/47.3.438 Yang, 2007, LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population, J. Formos. Med. Assoc., 106, 799, 10.1016/S0929-6646(08)60044-3 Shen, 2010, Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish, Arch. Intern. Med., 170, 1850, 10.1001/archinternmed.2010.384 Miserez, 1994, High prevalence of familial defective apolipoprotein B-100 in Switzerland, J. Lipid Res., 35, 574, 10.1016/S0022-2275(20)41171-X Humphries, 2006, Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing, J. Mol. Med., 84, 203, 10.1007/s00109-005-0019-z Liyanage, 2008, High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations, Ann. Clin. Biochem., 45, 170, 10.1258/acb.2007.007077 Benlian, 1996, Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100, Hum. Mutat., 7, 340, 10.1002/(SICI)1098-1004(1996)7:4<340::AID-HUMU8>3.0.CO;2-C Taylor, 2010, A double heterozygote for familial hypercholesterolaemia and familial defective apolipoprotein B-100, Ann. Clin. Biochem., 47, 487, 10.1258/acb.2010.010089 Rubinsztein, 1993, Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100, Arterioscler. Thromb., 13, 1076, 10.1161/01.ATV.13.7.1076 Benn, 2005, Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor, J. Biol. Chem., 280, 21052, 10.1074/jbc.M413877200 Hansen, 1997, Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries, Arterioscler. Thromb. Vasc. Biol., 17, 741, 10.1161/01.ATV.17.4.741 Pullinger, 1999, The apolipoprotein B R3531C mutation. Characteristics of 24 subjects from 9 kindreds, J. Lipid Res., 40, 318, 10.1016/S0022-2275(20)33372-1 Rabès, 2000, R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 20, E76, 10.1161/01.ATV.20.10.e76 Wenham, 1997, Familial ligand-defective apolipoprotein B-100: detection, biochemical features and haplotype analysis of the R3531C mutation in the UK, Atherosclerosis., 129, 185, 10.1016/S0021-9150(96)06029-7 Medeiros, 2010, Update of the Portuguese Familial Hypercholesterolaemia Study, Atherosclerosis., 212, 553, 10.1016/j.atherosclerosis.2010.07.012 Harada-Shiba, 1992, Siblings with normal LDL receptor activity and severe hypercholesterolemia, Arterioscler. Thromb., 12, 1071, 10.1161/01.ATV.12.9.1071 Zuliani, 1999, Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 19, 802, 10.1161/01.ATV.19.3.802 Norman, 1999, Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia, J. Clin. Invest., 104, 619, 10.1172/JCI6677 Jones, 2007, Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia, J. Clin. Invest., 117, 165, 10.1172/JCI29415 Abera, 2007, Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype, Clin. Chim. Acta., 378, 33, 10.1016/j.cca.2006.10.005 Arca, 2002, Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis, Lancet., 359, 841, 10.1016/S0140-6736(02)07955-2 Harada-Shiba, 2003, Clinical features and genetic analysis of autosomal recessive hypercholesterolemia, J. Clin. Endocrinol. Metab., 88, 2541, 10.1210/jc.2002-021487 Lind, 2004, Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment, J. Intern. Med., 256, 406, 10.1111/j.1365-2796.2004.01401.x Quagliarini, 2007, Autosomal recessive hypercholesterolemia in Spanish kindred due to a large deletion in the ARH gene, Mol. Genet. Metab., 92, 243, 10.1016/j.ymgme.2007.06.012 Rodenburg, 2004, A boy with autosomal recessive hypercholesterolaemia, Neth. J. Med., 62, 89 Thomas, 2004, Autosomal recessive hypercholesterolemia in three sisters with phenotypic homozygous familial hypercholesterolemia: diagnostic and therapeutic procedures, Ther. Apher. Dial., 8, 275, 10.1111/j.1526-0968.2004.00143.x Al-Kateb, 2003, A splice mutation in a Syrian autosomal recessive hypercholesterolemia family causes a two-nucleotide deletion of mRNA, Circ. Res., 93, e49, 10.1161/01.RES.0000089508.53350.70 Eden, 2002, Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1, J. Clin. Invest., 110, 1695, 10.1172/JCI0216445 Garcia, 2001, Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein, Science., 292, 1394, 10.1126/science.1060458 Wilund, 2002, Molecular mechanisms of autosomal recessive hypercholesterolemia, Hum. Mol. Genet., 11, 3019, 10.1093/hmg/11.24.3019 Filigheddu, 2009, Prevalence and clinical features of heterozygous carriers of autosomal recessive hypercholesterolemia in Sardinia, Atherosclerosis., 207, 162, 10.1016/j.atherosclerosis.2009.04.027 Ni, 2011, A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo, J. Lipid Res., 52, 78, 10.1194/jlr.M011445 Abifadel, 2010, Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents, Expert Opin. Ther. Pat., 20, 1547, 10.1517/13543776.2010.518615 Duff, 2011, PCSK9: an emerging target for treatment of hypercholesterolemia, Expert Opin. Ther. Targets., 15, 157, 10.1517/14728222.2011.547480 Horton, 2009, PCSK9: a convertase that coordinates LDL catabolism, J. Lipid Res., 50, S172, 10.1194/jlr.R800091-JLR200 Browning, 2010, Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans, J. Lipid Res., 51, 3359, 10.1194/jlr.P009860 Persson, 2010, Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans, Arterioscler. Thromb. Vasc. Biol., 30, 2666, 10.1161/ATVBAHA.110.214130 Herbert, 2010, Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control, Arterioscler. Thromb. Vasc. Biol., 30, 1333, 10.1161/ATVBAHA.110.204040 Welder, 2010, High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol, J. Lipid Res., 51, 2714, 10.1194/jlr.M008144 Dong, 2010, Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters, J. Lipid Res., 51, 1486, 10.1194/jlr.M003566 Ouguerram, 2004, Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9, Arterioscler. Thromb. Vasc. Biol., 24, 1448, 10.1161/01.ATV.0000133684.77013.88 Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc. Natl. Acad. Sci. USA., 102, 5374, 10.1073/pnas.0501652102 Le May, 2009, Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia, Arterioscler. Thromb. Vasc. Biol., 29, 684, 10.1161/ATVBAHA.108.181586 Abifadel, 2009, Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease, Hum. Mutat., 30, 520, 10.1002/humu.20882 Fasano, 2009, Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells, Atherosclerosis., 203, 166, 10.1016/j.atherosclerosis.2008.10.027 Pandit, 2008, Functional analysis of sites within PCSK9 responsible for hypercholesterolemia, J. Lipid Res., 49, 1333, 10.1194/jlr.M800049-JLR200 Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 Allard, 2005, Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia, Hum. Mutat., 26, 497, 10.1002/humu.9383 Taylor, 2010, Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project, Clin. Genet., 77, 572, 10.1111/j.1399-0004.2009.01356.x van der Graaf, 2011, Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children, Circulation., 123, 1167, 10.1161/CIRCULATIONAHA.110.979450 Pisciotta, 2006, Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia, Atherosclerosis., 186, 433, 10.1016/j.atherosclerosis.2005.08.015 Cohen, 2005, Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9, Nat. Genet., 37, 161, 10.1038/ng1509 Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am. J. Hum. Genet., 79, 514, 10.1086/507488 Fasano, 2007, A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol, Arterioscler. Thromb. Vasc. Biol., 27, 677, 10.1161/01.ATV.0000255311.26383.2f Cariou, 2009, PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia, Arterioscler. Thromb. Vasc. Biol., 29, 2191, 10.1161/ATVBAHA.109.194191 Lakoski, 2009, Genetic and metabolic determinants of plasma PCSK9 levels, J. Clin. Endocrinol. Metab., 94, 2537, 10.1210/jc.2009-0141 Zelcer, 2009, LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor, Science., 325, 100, 10.1126/science.1168974 Matsuoka, 2010, Competitive solubilization of cholesterol and six species of sterol/stanol in bile salt micelles, Chem. Phys. Lipids., 163, 397, 10.1016/j.chemphyslip.2010.03.006 Amiot, 2011, Phytosterol ester processing in the small intestine: impact on cholesterol availability for absorption and chylomicron cholesterol incorporation in healthy humans, J. Lipid Res., 52, 1256, 10.1194/jlr.M013730 Jones, 2009, Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer, Curr. Opin. Clin. Nutr. Metab. Care., 12, 147, 10.1097/MCO.0b013e328326770f Brufau, 2011, A reappraisal of the mechanism by which plant sterols promote neutral sterol loss in mice, PLoS ONE., 6, e21576, 10.1371/journal.pone.0021576 Lin, 2011, Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans, Circulation., 124, 596, 10.1161/CIRCULATIONAHA.110.006692 Kwon, 2011, The structure of the NPC1L1 N-terminal domain in a closed conformation, PLoS ONE., 6, e18722, 10.1371/journal.pone.0018722 Wang, 2009, Membrane topology of human NPC1L1, a key protein in enterohepatic cholesterol absorption, J. Lipid Res., 50, 1653, 10.1194/jlr.M800669-JLR200 Betters, 2010, NPC1L1 and cholesterol transport, FEBS Lett., 584, 2740, 10.1016/j.febslet.2010.03.030 Weinglass, 2008, Extracellular loop C of NPC1L1 is important for binding to ezetimibe, Proc. Natl. Acad. Sci. USA., 105, 11140, 10.1073/pnas.0800936105 Read, 2000, A mechanism of membrane neutral lipid acquisition by the microsomal triglyceride transfer protein, J. Biol. Chem., 275, 30372, 10.1074/jbc.C000364200 Shoulders, 2005, Current biology of MTP: implications for selective inhibition, Curr. Top. Med. Chem., 5, 283, 10.2174/1568026053544560 Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200 Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat. Struct. Mol. Biol., 14, 413, 10.1038/nsmb1235 Fisher, 2006, Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors, Mol. Cell., 22, 277, 10.1016/j.molcel.2006.02.021 Mann, 1989, Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia, Biochim. Biophys. Acta., 1005, 239, 10.1016/0005-2760(89)90043-X Moriyama, 1992, Apolipoprotein E1 Lys-146-Glu with type III hyperlipoproteinemia, Biochim. Biophys. Acta., 1128, 58, 10.1016/0005-2760(92)90257-V Hoffer, 1996, Apolipoprotein E1-Hammersmith (Lys146 → Asn;Arg147 → Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia, Atherosclerosis., 124, 183, 10.1016/0021-9150(96)05819-4 Dong, 1996, Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins, J. Biol. Chem., 271, 19053, 10.1074/jbc.271.32.19053 Hatters, 2005, Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms, J. Biol. Chem., 280, 34288, 10.1074/jbc.M506044200 Nguyen, 2010, Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4, Biochemistry., 49, 10881, 10.1021/bi1017655 Tetali, 2010, VLDL lipolysis products increase VLDL fluidity and convert apolipoprotein E4 into a more expanded conformation, J. Lipid Res., 51, 1273, 10.1194/jlr.M000406 Guttman, 2010, Decoding of lipoprotein-receptor interactions: properties of ligand binding modules governing interactions with apolipoprotein E, Biochemistry., 49, 1207, 10.1021/bi9017208 Sivashanmugam, 2009, A unified scheme for initiation and conformational adaptation of human apolipoprotein E N-terminal domain upon lipoprotein binding and for receptor binding activity, J. Biol. Chem., 284, 14657, 10.1074/jbc.M901012200 Morrow, 2000, Effect of arginine 172 on the binding of apolipoprotein E to the low density lipoprotein receptor, J. Biol. Chem., 275, 2576, 10.1074/jbc.275.4.2576 Croy, 2004, Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1, Biochemistry., 43, 7328, 10.1021/bi036208p Guttman, 2010, Structure of the minimal interface between ApoE and LRP, J. Mol. Biol., 398, 306, 10.1016/j.jmb.2010.03.022 Ruiz, 2005, The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor, J. Lipid Res., 46, 1721, 10.1194/jlr.M500114-JLR200 Sanna, 2011, Fine mapping of five loci associated with low-density lipoprotein cholesterol detects variants that double the explained heritability, PLoS Genet., 7, e1002198, 10.1371/journal.pgen.1002198 Koeijvoets, 2005, Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study, Atherosclerosis., 180, 93, 10.1016/j.atherosclerosis.2004.10.042 Koeijvoets, 2005, Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial, Circulation., 112, 3168, 10.1161/CIRCULATIONAHA.105.565507 Guardamagna, 2009, The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia, J. Pediatr., 155, 199, 10.1016/j.jpeds.2009.02.022 Ceska, 2000, Familial defective apolipoprotein B-100: a lesson from homozygous and heterozygous patients, Physiol. Res., 49, S125 Leren, 2004, Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia, Clin. Genet., 65, 419, 10.1111/j.0009-9163.2004.0238.x Naoumova, 2005, Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response, Arterioscler. Thromb. Vasc. Biol., 25, 2654, 10.1161/01.ATV.0000190668.94752.ab Ken-Dror, 2010, APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men, Mol. Med., 16, 389, 10.2119/molmed.2010.00044 Waterworth, 2010, Genetic variants influencing circulating lipid levels and risk of coronary artery disease, Arterioscler. Thromb. Vasc. Biol., 30, 2264, 10.1161/ATVBAHA.109.201020 Ward, 2009, APOE genotype, lipids, and coronary heart disease risk: a prospective population study, Arch. Intern. Med., 169, 1424, 10.1001/archinternmed.2009.234 Burman, 2009, Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada, Atherosclerosis., 203, 192, 10.1016/j.atherosclerosis.2008.06.007 Mega, 2009, Identification of genetic variants associated with response to statin therapy, Arterioscler. Thromb. Vasc. Biol., 29, 1310, 10.1161/ATVBAHA.109.188474 Huang, 2009, Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study, Circ. Cardiovasc. Genet., 2, 354, 10.1161/CIRCGENETICS.108.828467 Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N. Engl. J. Med., 354, 1264, 10.1056/NEJMoa054013 Chen, 2005, A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis, J. Am. Coll. Cardiol., 45, 1611, 10.1016/j.jacc.2005.01.051 Guella, 2010, Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population, J. Lipid Res., 51, 3342, 10.1194/jlr.M010009 Chasman, 2008, Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication, Circ. Cardiovasc. Genet., 1, 21, 10.1161/CIRCGENETICS.108.773168 Benn, 2010, PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses, J. Am. Coll. Cardiol., 55, 2833, 10.1016/j.jacc.2010.02.044 Miljkovic, 2010, Association analysis of 33 lipoprotein candidate genes in multi-generational families of African ancestry, J. Lipid Res., 51, 1823, 10.1194/jlr.M003897